States

Latest California Healthline Stories

KFF Health News' 'What the Health?': Anti-Abortion Hard-Liners Speak Up

While Republican candidates in many states downplay their opposition to abortion, the most vehement wing of the movement, which helped overturn Roe v. Wade — those who advocate prosecuting patients, outlawing contraception, and banning IVF — are increasingly outspoken. Meanwhile, some state legislatures continue to advance new restrictions, like a proposal moving in Louisiana to include abortion medications mifepristone and misoprostol on the list of the most dangerous drugs. Alice Miranda Ollstein of Politico, Rachel Roubein of The Washington Post, and Joanne Kenen of the Johns Hopkins schools of public health and nursing and Politico Magazine join KFF Health News’ Julie Rovner to discuss these stories and more. Also this week, Rovner interviews Shefali Luthra of The 19th about her new book on abortion in post-Roe America, “Undue Burden.”

California Pays People With Addiction To Stay Clean — With Feds’ Blessing

Led by California, a few states are testing an experimental program that pays people to stop using hard drugs. The Golden State was the first to win approval from the Biden administration to cover the sobriety payments, with Medicaid wrapping it into an ambitious health-care initiative spearheaded by Democratic Gov. Gavin Newsom to provide the […]

Los Angeles County Launches Ambitious Plan To Tackle Medical Debt. Hospitals Groan.

Los Angeles County, the nation’s most populous county, is spearheading a comprehensive plan to tackle a $2.9 billion medical debt crisis. Hospitals are still getting on board with the project, which is helmed by the public health department.

La vacuna contra el sarampión es segura y eficaz. No te dejes engañar por los escépticos

Este año, el 80% de los casos ha sido en personas no vacunadas o con un estatus de vacunación desconocido. Muchos padres han sido influenciados por una avalancha de desinformación difundida por políticos y personalidades en redes sociales, podcasts, y en la TV.

High Price of Popular Diabetes Drugs Deprives Low-Income People of Effective Treatment

The makers of Ozempic and Mounjaro charge list prices of around $1,000 a month for the diabetes and obesity drugs, and insurers are reluctant to pick up the tab. Often, low-income patients have to resort to less effective treatments.

Personas de bajos ingresos no pueden recibir terapias efectivas contra la diabetes por el alto costo

La escasez de suministros y las barreras que ponen las aseguradoras para obtener esta poderosa clase de medicamentos, llamados agonistas de GLP-1, han dejado a muchas personas que viven con diabetes y obesidad sin los medicamentos que necesitan para mantenerse saludables.